REMS Are Not The Right Weapon Against Antibiotic Resistance, FDA Says
Executive Summary
Risk Evaluation and Mitigation Strategies would not be useful against the development of antibiotic resistance, FDA concluded after an advisory committee member suggested using REMS to limit use of Actavis' antibiotic Avycaz to slow emergence of resistant bacteria.